Anastasios Gianakakos

CIK 1413822 · President & CEO · last filed 2026-06-22

Anastasios Gianakakos is a President & CEO who has filed 123 SEC Form 4 insider transactions across 4 companies since 2008. The most recent filing, for KARD, was dated Jun 22, 2026. Across all open-market trades the lifetime net is −$17.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $124.0M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$123.96M
Companies
4
Total Filings
123
Lifetime Open-Market Net
-$17.46M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

MYOK price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
333 ALLERTON AVE.
SOUTH SAN FRANCISCO, CA 94080
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count in each company: direct shares plus every indirect holder (trusts, LLCs, partnerships, family members) on the latest Form 4 that lists them. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
KARD President & CEO 9,806,633 $12.64 $123.96M $0 1 2026-06-22
LianBio (LIAN) Delisted Director 363,253 $0.32 $115.9K $0 4 2024-02-20
MyoKardia, Inc. (MYOK) Delisted President and CEO 624,790 — — -$13.62M 64 2020-07-07
MAP Pharmaceuticals, Inc. (MAPP) Delisted SVP, Chief Business Officer 0 $28.11 $0 -$3.84M 53 2013-03-04

Holdings By Holder

Who holds the shares on record: the insider directly, and each trust, LLC, partnership or family member reported as an indirect holder on the latest Form 4 that lists them. Holder names come from the filing's footnotes. Rows under No longer reported appeared on earlier filings but not the latest one, usually because the holder was emptied or folded into another; they are not counted in the total.
Symbol Holder Shares Share of Total Reported
KARD Direct 49,821 0.5% 2026-06-22
By AEG 2021 Trust 5,665,090 57.8% 2026-06-22
By KCM 2023 Trust 2,422,520 24.7% 2026-06-22
By MJA Legacy Trust dated May 6, 2020 1,165,732 11.9% 2026-06-22
By spouse 498,692 5.1% 2026-06-22
By Katina Mandas 2024 Qualified Annuity Trust dated April 29, 2024 4,778 0.0% 2026-06-22
Total 9,806,633
LIAN Direct 53,630 14.8% 2024-02-20
By Trust 309,623 85.2% 2024-02-20
Total 363,253
MYOK Direct 19,122 3.1% 2020-07-07
By Reporting Person's Trust 4 300,000 48.0% 2020-07-07
By Reporting Person's Trust 2 129,407 20.7% 2020-07-07
By Trust 2 53,087 8.5% 2020-07-07
By Trust 1 53,087 8.5% 2020-07-07
By Trust 3 53,087 8.5% 2020-07-07
By reporting Person's Trust 6 10,000 1.6% 2020-07-07
By Reporting Person's Trust 5 7,000 1.1% 2020-07-07
Total 624,790
No longer reported
By Reporting Person's Trust 3 0 — last 2020-04-20
By The James Gianakakos 2015 Irrevocable Trust Dtd 9/26/2015 12,200 — last 2018-02-07
By The Alexander Gianakakos 2015 Irrevocable Trust dtd 9/26/2015 12,200 — last 2018-02-07
By The Gianakakos Family Revocable Trust DTD 11/02/2006 85,973 — last 2018-02-07
By The Tassos Gianakakos 2018 Annuity Trust dtd 1/6/2018 500,000 — last 2018-02-07
By The Emmanuel Gianakakos 2015 Irrevocable Trust Dtd 9/26/2015 12,200 — last 2018-02-07
By Reporting Person's Trust 181,169 — last 2018-01-16
Tassos Gianakakos 2015 Annuity Trust, dated September 25, 2015
Trust
181,169 — last 2017-11-03
By Trust 181,169 — last 2017-03-22

Recent Filings

123 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144, so not all of them end in a sale. Under each notice: the role the filer ticked on it, and whether a sale followed (a Form 4 sale within 30 days, or a sale listed on a later notice).
Filed Symbol Action Net Shares Net $ Link
2026-06-22 KARD Conv (C) +568,395 $0 EDGAR
2024-02-20 LianBio (LIAN) Delisted Mixed +17,082 -$2 EDGAR
2023-06-23 LianBio (LIAN) Delisted Grant (A) — $0 EDGAR
2022-06-27 LianBio (LIAN) Delisted Grant (A) — $0 EDGAR
2022-01-03 LianBio (LIAN) Delisted Exer (M) +36,548 $237.2K EDGAR
2020-11-19 — Mixed −747,073 $0
2020-07-07 MyoKardia, Inc. (MYOK) Delisted Sell (S) −5,000 -$469.9K EDGAR
2020-06-04 MyoKardia, Inc. (MYOK) Delisted Sell (S) −5,000 -$514.2K EDGAR
2020-05-20 MyoKardia, Inc. (MYOK) Delisted Sell (S) −10,000 -$1.25M EDGAR
2020-05-13 MyoKardia, Inc. (MYOK) Delisted Sell (S) −25,000 -$2.55M EDGAR
Showing 1–10 of 123
Page 1 of 13
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).